[{"address1": "62 Lygon Street", "address2": "Level 3", "city": "Carlton", "state": "VIC", "zip": "3053", "country": "Australia", "phone": "61 3 9824 5254", "fax": "61 3 9822 7735", "website": "https://www.radiopharmtheranostics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Av\u00df6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTP\u00b5 glioblastoma diagnostic; and RAD602, a PTP\u00b5 glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 69, "title": "Founder & Executive Chairman", "yearBorn": 1956, "fiscalYear": 2025, "totalPay": 223603, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Riccardo  Canevari", "title": "MD, CEO & Director", "fiscalYear": 2025, "totalPay": 1265858, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Phillip  Hains", "title": "CFO & Joint Company Secretary", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dimitris  Voliotis M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2025, "totalPay": 737141, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hitesh  Goel", "title": "Head of Project Management", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Jong C.A.", "title": "Joint Company Secretary", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 4.99, "open": 4.88, "dayLow": 4.82, "dayHigh": 5.05, "regularMarketPreviousClose": 4.99, "regularMarketOpen": 4.88, "regularMarketDayLow": 4.82, "regularMarketDayHigh": 5.05, "payoutRatio": 0.0, "beta": 0.938, "forwardPE": -1.9601117, "volume": 34573, "regularMarketVolume": 34573, "averageVolume": 727500, "averageVolume10days": 31820, "averageDailyVolume10Day": 31820, "bid": 3.59, "ask": 6.23, "bidSize": 2, "askSize": 2, "marketCap": 39809984, "fiftyTwoWeekLow": 3.496, "fiftyTwoWeekHigh": 16.25, "allTimeHigh": 50.82, "allTimeLow": 3.496, "priceToSalesTrailing12Months": 3.1816988, "fiftyDayAverage": 5.02016, "twoHundredDayAverage": 5.07708, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 11911958528, "profitMargins": 0.0, "floatShares": 1581678227, "sharesOutstanding": 7883165, "sharesShort": 15105, "sharesShortPriorMonth": 25588, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0019, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.02544, "shortRatio": 0.01, "shortPercentOfFloat": 0.0023999999, "impliedSharesOutstanding": 7883165, "bookValue": 0.01337467, "priceToBook": 377.5794, "lastFiscalYearEnd": 1751241600, "nextFiscalYearEnd": 1782777600, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -38342456, "trailingEps": -3.72, "forwardEps": -2.5763838, "enterpriseToRevenue": 952.029, "enterpriseToEbitda": -366.129, "52WeekChange": 0.1399548, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 5.05, "targetHighPrice": 29.872562, "targetLowPrice": 13.617688, "targetMeanPrice": 17.859053, "targetMedianPrice": 15.736769, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 29116836, "totalCashPerShare": 0.012, "ebitda": -32534884, "totalDebt": 0, "quickRatio": 2.646, "currentRatio": 2.669, "totalRevenue": 12512179, "revenuePerShare": 1.8, "returnOnAssets": -0.27702, "returnOnEquity": -1.09199, "grossProfits": -18597160, "freeCashflow": -23615530, "operatingCashflow": -36645476, "grossMargins": -1.48632, "ebitdaMargins": -2.60026, "operatingMargins": -1.52112, "financialCurrency": "AUD", "symbol": "RADX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1733409000000, "shortName": "Radiopharm Theranostics Limited", "longName": "Radiopharm Theranostics Limited", "postMarketChangePercent": -0.99010277, "postMarketPrice": 5.0, "postMarketChange": -0.05000019, "regularMarketChange": 0.06000042, "regularMarketDayRange": "4.82 - 5.05", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 727500, "fiftyTwoWeekLowChange": 1.5540001, "fiftyTwoWeekLowChangePercent": 0.44450805, "fiftyTwoWeekRange": "3.496 - 16.25", "fiftyTwoWeekHighChange": -11.2, "fiftyTwoWeekHighChangePercent": -0.68923074, "fiftyTwoWeekChangePercent": 13.995481, "epsTrailingTwelveMonths": -3.72, "epsForward": -2.5763838, "epsCurrentYear": -3.285, "priceEpsCurrentYear": -1.5372907, "fiftyDayAverageChange": 0.029839993, "fiftyDayAverageChangePercent": 0.0059440318, "twoHundredDayAverageChange": -0.027079582, "twoHundredDayAverageChangePercent": -0.0053336923, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1769820678, "regularMarketTime": 1769806801, "exchange": "NCM", "messageBoardId": "finmb_1685428878", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.2024132, "regularMarketPrice": 5.05, "marketState": "CLOSED", "displayName": "Radiopharm Theranostics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]